All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
On 21 June 2018, a study (NCT01954979) was published in Blood assessing the safety, efficacy, and immune effects of abatacept, a recombinant soluble fusion protein inhibiting T cell activation via blockade of co-stimulation, for the treatment of steroid-refractory chronic graft-versus-host disease (SR-cGvHD).1 The paper was published by Myrna R. Nahas from Beth Israel Deaconess Medical Center, Section of Hematological Malignancies and Bone Marrow Transplantation, Harvard Medical School, Boston, MA, USA, and colleagues.
Sixteen heavily pre-treated patients (median age = 54 years; range 24–72) with SR-cGvHD were enrolled between April 2014 and October 2015 in this phase I dose-escalation study, which followed a 3+3 design with two escalating doses of abatacept to determine the maximum tolerated dose: 3 mg/kg (n = 3) and 10 mg/kg (n = 3). An additional expansion cohort was treated at a dose of 10 mg/kg (n = 10). The most commonly affected organ systems were skin (94%), joints (81%), mouth (75%), and eyes (75%).
The authors concluded that abatacept was well-tolerated “with pulmonary infections being the only grade 3 or 4 possibly related adverse events observed in this phase I study.” Furthermore, no dose-limiting toxicities were observed. The authors added that abatacept showed a clinical response in 44% of patients as well as it was able to reduce prednisone usage by 51.3%. Based on this data, a phase II study is ongoing.
An overview of EBMT recommendations on prophylaxis and treatment of acute and chronic GvHD
A summary of the European Society for Blood and Marrow Transplantation (EBMT) webinar entitled ‘Prophylaxis and management of GvHD’ delivered by Olaf Penack on...
Clinical features of cGvHD following cord blood infused haploidentical transplantation
An open-label, non-randomized study found the immunomodulatory effects of cellular components in the umbillical cord were unique, but that further study was...
Subscribe to get the best content related to GvHD delivered to your inbox